Neuropsychiatric symptoms after liver transplantation in a 65-year-old male patient
Loading...
Identifiers
Publication date
Advisors
Tutors
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
MDPI
Abstract
The development of immunosuppressants has been key for the advancement of solid
organ transplant surgery. Specifically, cyclosporine, tacrolimus, or everolimus have significantly
increased the survival rate of patients by reducing the risk of a rejection of the transplanted organ
and limiting graft-versus-host disease. We report the case of a 65-year-old man who, after undergoing
a liver transplantation and receiving an immunosuppressive treatment with cyclosporine
and everolimus, presented severe obsessive, psychotic, and behavioral symptoms over the past
three years, and describe the pharmacological and non-pharmacological interventions implemented
against these symptoms. In this case, the immunosuppressants used have been cyclosporine and,
preferably, everolimus. On the other hand, potential adverse reactions to the treatment have been
observed, including neuropsychiatric symptoms such as tremor, anxiety, dysthymia, psychosis, and
behavioral disorders, which make it necessary to use corrective psychoactive drugs such as benzodiazepines,
antidepressants, and antipsychotics, combined with non-pharmacological interventions. A
transversal approach, from the medical and psychosocial disciplines, facilitates success in managing
neuropsychiatric symptoms after soft organ transplants
Description
Bibliographic citation
Bugallo-Carrera, C.; Facal, D.; Domínguez-Lenogue, C.; Álvarez-Vidal, V.; Gandoy-Crego, M.; Caamaño-Ponte, J. Neuropsychiatric symptoms after liver transplantation in a 65-year-old male patient. Brain Sci. 2022, 12, 1721
Relation
Has part
Has version
Is based on
Is part of
Is referenced by
Is version of
Requires
Publisher version
https://doi.org/10.3390/brainsci12121721Sponsors
Rights
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/)







